Table 4 Reported adverse events with long-term golimumab treatment.
From: Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients
Type of adverse event | N (%) |
|---|---|
Infections | |
Respiratory: mild respiratory infections (3), tracheobronchitis (1), pneumonia (1a,b), pneumonitis (1), influenza (1) | 15 (44.1%) |
Urinary: urinary tract infections (5) | |
Gastrointestinal: acute gastroenteritis (1) | |
Otolaryngology (ENT): tonsillitis (1) | |
Others: mononucleosis (1b) | |
Skin process | |
Rash at the injection site (1), folliculitis (1), pruritus and urticaria (1), eczema-like rash with psoriatic distribution (2a), rash (1) | 6 (17.6%) |
Neurological processes | |
Myelitis (2a,b), headaches (2), dizziness (1) | 5 (14.7%) |
Arthropathies | |
Reactive knee arthritis (1a,b), arthralgia (1) | 2 (5.8%) |
Heart disease | |
Heart failure (1a,b) | 1 (2.9%) |
Others | |
Lupus-like condition (1a,b), leukopenia (1), fever (2a,b), bronchospasm (1) | 5 (14.7%) |
Total | 34 (100%) |
